Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q6523413> ?p ?o }
Showing triples 1 to 41 of
41
with 100 triples per page.
- Q6523413 subject Q8802906.
- Q6523413 subject Q9052781.
- Q6523413 abstract "Lenvatinib (E7080; trade name Lenvima) is a multi-kinase inhibitor developed by Eisai Co. It inhibits both VEGFR2 and VEGFR3 kinases.Lenvatinib was granted orphan drug status for the treatment of various types of thyroid cancer that do not respond to radioiodine in the US and Japan in 2012 and in Europe in 2013.In February 2015, the FDA granted approval to lenvatinib for treatment of progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). In May 2015, EMA granted approval to lenvatinib for the same indication.Jan 2016: The US FDA have accepted it for Priority Review for the treatment of unresectable advanced or metastatic renal cell carcinoma (RCC) in combination with everolimus following one prior vascular endothelial growth factor (VEGF) targeted therapy. This was after encouraging PFS results from a phase III trial.".
- Q6523413 atcPrefix "L01".
- Q6523413 atcSuffix "XE29".
- Q6523413 casNumber "417716-92-8".
- Q6523413 chEBI "85994".
- Q6523413 fdaUniiCode "EE083865G2".
- Q6523413 iupacName "4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide".
- Q6523413 pubchem "9823820".
- Q6523413 thumbnail Lenvatinib_skeletal.svg?width=300.
- Q6523413 wikiPageWikiLink Q1164529.
- Q6523413 wikiPageWikiLink Q1208453.
- Q6523413 wikiPageWikiLink Q1367466.
- Q6523413 wikiPageWikiLink Q17928864.
- Q6523413 wikiPageWikiLink Q18028241.
- Q6523413 wikiPageWikiLink Q204711.
- Q6523413 wikiPageWikiLink Q2112244.
- Q6523413 wikiPageWikiLink Q29725.
- Q6523413 wikiPageWikiLink Q492646.
- Q6523413 wikiPageWikiLink Q7180990.
- Q6523413 wikiPageWikiLink Q7251487.
- Q6523413 wikiPageWikiLink Q826522.
- Q6523413 wikiPageWikiLink Q8802906.
- Q6523413 wikiPageWikiLink Q903384.
- Q6523413 wikiPageWikiLink Q9052781.
- Q6523413 atcPrefix "L01".
- Q6523413 atcSuffix "XE29".
- Q6523413 casNumber "417716".
- Q6523413 chebi "85994".
- Q6523413 iupacName "4".
- Q6523413 pubchem "9823820".
- Q6523413 unii "EE083865G2".
- Q6523413 type ChemicalSubstance.
- Q6523413 type Drug.
- Q6523413 type ChemicalObject.
- Q6523413 type Thing.
- Q6523413 type Q8386.
- Q6523413 comment "Lenvatinib (E7080; trade name Lenvima) is a multi-kinase inhibitor developed by Eisai Co. It inhibits both VEGFR2 and VEGFR3 kinases.Lenvatinib was granted orphan drug status for the treatment of various types of thyroid cancer that do not respond to radioiodine in the US and Japan in 2012 and in Europe in 2013.In February 2015, the FDA granted approval to lenvatinib for treatment of progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).".
- Q6523413 label "Lenvatinib".
- Q6523413 depiction Lenvatinib_skeletal.svg.